Evidence map›Paper›PMID 41071193›Full record

ArticleCancer immunology, immunotherapy : CII2025

Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer.

Ning Mao, Cui He, Jia Kuang, Chunguang Wang, Zhao Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ning MaoDepartment of Cardiothoracic Surgery, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Cui HeDepartment of Blood Transfusion, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Jia KuangDepartment of Neurology, The Affiliated Yongchuan Hospital of Chongqing Medical University, No. 439, Xuanhua Road, Yongchuan District, Chongqing, 402160, China.
Chunguang WangDepartment of Oncology, The Affiliated Yongchuan Hospital of Chongqing Medical University, No. 439, Xuanhua Road, Yongchuan District, Chongqing, 402160, China. 1783084236@qq.com.
Zhao YangDepartment of Neurology, The Affiliated Yongchuan Hospital of Chongqing Medical University, No. 439, Xuanhua Road, Yongchuan District, Chongqing, 402160, China. yangzhao5140@sohu.com.

Funding

Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) No. 2024MSXM023the Yongchuan Hospital of Chongqing Medical University Research Project No. YJJL2024083
6 · The paper itself

Abstract

backgroundImmune checkpoint blockade (ICB) has revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), yet primary resistance remains a significant clinical challenge. Recent evidence implicates PRAS40 (AKT1S1) in regulating cellular survival and immune responses, but its role in immunotherapy resistance is not fully understood.

methodsTranscriptomic data from TCGA and GTEx cohorts were analyzed to assess PRAS40 expression. Prognostic value was evaluated using Cox regression. Immune microenvironment features were characterized with CIBERSORT and TIMER. Predictive efficacy for ICB response was examined using TIDE and IPS. Plasma PRAS40 levels in 66 NSCLC patients receiving ICB were quantified by proximity extension assay (PEA), and multiplex immunohistochemistry assessed associations among PRAS40, PD-L1, and CD8

resultsHigh PRAS40 expression was associated with poor prognosis, reduced CD8

conclusionPRAS40 is strongly associated with primary ICB resistance in NSCLC and may serve as a novel predictive biomarker. These findings support its potential to guide personalized immunotherapy in lung cancer.

Indexed as

Adaptor Proteins, Signal TransducingBiomarkers, TumorCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmImmune Checkpoint InhibitorsLung NeoplasmsAgedCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedPrognosisProteomicsTumor MicroenvironmentAdaptor Proteins, Signal TransducingAKT1S1 protein, humanBiomarkers, TumorImmune Checkpoint InhibitorsBiomarkerDrug resistanceImmune checkpoint blockadeImmunotherapyNon-small cell lung cancer

Identifiers

PMID41071193
PMCPMC12514079

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.